



November 07, 2019

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

**Sub: Investor Presentation**

**Ref: HealthCare Global Enterprises Limited (“the Company”) (NSE Scrip Code: HCG/  
BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held on this day, 7<sup>th</sup> November 2019, *inter alia*, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2019.

In this respect, we enclose herewith the Presentation on the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2019.

Request you to take this on record.

**For HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

Encl: as above

**HealthCare Global Enterprises Limited**

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

# HealthCare Global Enterprises Limited

## Investor Presentation Q2 & H1-FY20



THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation has been prepared by HealthCare Global Enterprises Limited (the "Company"). These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

# Leadership in specialty healthcare



# Hope

For cancer patients





**Financial Highlights**

---



**Operating Highlights**



**Key Financial  
Information**



**Project Updates**

# Financial Highlights: Q2-FY20

INR million except earnings per share

Period Ended Sep 30	Q2-FY20 As per AS 116	Q2-FY19	Growth (y-o-y)	Q2-FY20 w/o AS 116	Growth (y-o-y)
<b>Income from Operations</b>	<b>2,785</b>	<b>2,453</b>	<b>13.5%</b>	<b>2,785</b>	<b>13.5%</b>
Other Income	15	23		15	
<b>EBITDA<sup>(1)</sup></b>	<b>471</b>	<b>358</b>	<b>31.7%</b>	<b>340</b>	<b>-4.9%</b>
EBITDA Margin (%)	16.8%	14.4%		12.1%	
<b>Operating EBITDA<sup>(2)</sup></b>	<b>456</b>	<b>335</b>	<b>36.1%</b>	<b>325</b>	<b>-3.0%</b>
Operating EBITDA Margin (%)	16.4%	13.7%		11.7%	
<b>PBT<sup>(3)</sup></b>	<b>(269)</b>	<b>(103)</b>	<b>NM</b>	<b>(179)</b>	<b>NM</b>
PBT Margin (%)	-9.7%	-4.2%		-6.4%	
<b>PAT<sup>(4)</sup></b>	<b>(223)</b>	<b>(65)</b>	<b>NM</b>	<b>(141)</b>	<b>NM</b>
PAT Margin (%)	-8.0%	-2.6%		-5.1%	
<b>Earnings Per Share</b>	<b>(2.51)</b>	<b>(0.74)</b>	<b>NM</b>	<b>(1.60)</b>	<b>NM</b>

- 1) Profit before depreciation/amortization, finance costs, exceptional items and taxes
- 2) EBITDA excluding other Income
- 3) Profit / (Loss) before tax and after share of profit / (loss) of equity accounted investee
- 4) Profit / (Loss) for the period after share of profit / (loss) of equity accounted investee, taxes and minority interests

- **Q2'20 Revenue grew 13.5% y-o-y**
  - HCG<sup>(1)</sup> centers: **+13.2%**
  - Milann<sup>(2)</sup> centers: **+17.7%**
- **Q2'20 Operating EBITDA**
  - Existing centers<sup>(3)(4)</sup>: INR 417 Mn (**17.7%** margin vs 18.5% margin in Q2-FY19)
  - New centers<sup>(5)</sup>: Loss of INR **(92)** Mn (vs. loss of INR (73) Mn in Q2-FY19)

- (1) 21 comprehensive cancer centers, 3 multispecialty hospitals, 3 diagnostic centers and 1 multispecialty hospital managed by HCG. Trichy is no longer included as HCG center
- (2) 8 fertility centers operated under "Milann" brand
- (3) Existing centers now include HCG centers in Gulbarga, Vizag, Bhavnagar and Baroda as well as Milann center in MSR Bangalore
- (4) Corporate cost allocated between existing and new centers in proportion to gross block
- (5) 7 HCG centers and 4 Milann centers that commenced operation after April 1, 2016

Note: Effective 1 April 2019, the Company has adopted IND AS 116 'Leases' standards, applied to lease contracts existing on 1 April 2019. The effect of this adoption for the year ended 31 March 2019 have not been retrospectively adjusted. Unless specified, the EBITDA numbers exclude IND AS 116 adjustments.

# Financial Highlights: H1-FY20

INR million except earnings per share

Period Ended Sep 30	H1-FY20 As per AS 116	H1-FY19	Growth (y-o-y)	H1-FY20 w/o AS 116	Growth (y-o-y)
<b>Income from Operations</b>	<b>5,473</b>	<b>4,719</b>	<b>16.0%</b>	<b>5,473</b>	<b>16.0%</b>
Other Income	28	32		28	
<b>EBITDA<sup>(1)</sup></b>	<b>933</b>	<b>673</b>	<b>38.7%</b>	<b>658</b>	<b>-2.2%</b>
EBITDA Margin (%)	16.9%	14.2%		12.0%	
<b>Operating EBITDA<sup>(2)</sup></b>	<b>904</b>	<b>641</b>	<b>41.2%</b>	<b>629</b>	<b>-1.7%</b>
Operating EBITDA Margin (%)	16.5%	13.6%		11.5%	
<b>PBT<sup>(3)</sup></b>	<b>(497)</b>	<b>(180)</b>	<b>NM</b>	<b>(324)</b>	<b>NM</b>
PBT Margin (%)	-9.1%	-3.8%		-5.9%	
<b>PAT<sup>(4)</sup></b>	<b>(403)</b>	<b>(99)</b>	<b>NM</b>	<b>(241)</b>	<b>NM</b>
PAT Margin (%)	-7.4%	-2.1%		-4.4%	
<b>Earnings Per Share</b>	<b>(4.56)</b>	<b>(1.12)</b>	<b>NM</b>	<b>(2.74)</b>	<b>NM</b>

- 1) Profit before depreciation/amortization, finance costs, exceptional items and taxes
- 2) EBITDA excluding other Income
- 3) Profit / (Loss) before tax and after share of profit / (loss) of equity accounted investee
- 4) Profit / (Loss) for the period after share of profit / (loss) of equity accounted investee, taxes and minority interests

- **H1'20 Revenue grew 16.0% y-o-y**
  - HCG<sup>(1)</sup> centers: **+16.1%**
  - Milann<sup>(2)</sup> centers: **+14.4%**
- **H1'20 Operating EBITDA**
  - Existing centers<sup>(3)(4)</sup>: INR 812 Mn (**17.4%** margin vs 18.0% margin in H1-FY19)
  - New centers<sup>(5)</sup>: Loss of INR **(182)** Mn (vs. loss of INR (129) Mn in H1-FY19)

- (1) 21 comprehensive cancer centers, 3 multispecialty hospitals, 3 diagnostic centers and 1 multispecialty hospital managed by HCG. Trichy is no longer included as HCG center
- (2) 8 fertility centers operated under "Milann" brand
- (3) Existing centers now include HCG centers in Gulbarga, Vizag, Bhavnagar and Baroda as well as Milann center in MSR Bangalore
- (4) Corporate cost allocated between existing and new centers in proportion to gross block
- (5) 7 HCG centers and 4 Milann centers that commenced operation after April 1, 2016

Note: Effective 1 April 2019, the Company has adopted IND AS 116 'Leases' standards, applied to lease contracts existing on 1 April 2019. The effect of this adoption for the year ended 31 March 2019 have not been retrospectively adjusted. Unless specified, the EBITDA numbers exclude IND AS 116 adjustments.

# Revenue Mix: Q2-FY20

**Revenue:**  
INR 2,785 Mn


**HCG Centers:**  
INR 2,597 Mn



HCG (1)  
centers  
**93%**  
(93%)<sup>1</sup>



Fertility<sup>(2)</sup>  
centers  
**7%**  
(7%)<sup>1</sup>



Karnataka  
35%  
(38%)<sup>1</sup>

Gujarat  
30%  
(28%)<sup>1</sup>

North India  
2%  
(1%)<sup>1</sup>

Tamil Nadu  
4%  
(4%)<sup>1</sup>

A.P.  
7%  
(8%)<sup>1</sup>

East India  
8%  
(7%)<sup>1</sup>

Maharashtra  
14%  
(14%)<sup>1</sup>

(1) 21 comprehensive cancer centers, 3 multispecialty hospitals, 3 diagnostic centers and 1 multispecialty hospital managed by HCG, as at September 30 2019

(2) 8 fertility centers operated under "Milann" brand

<sup>1</sup>(Q2-FY19)



# HCG Centers: Q2-FY20 Revenues

INR million

Period Ended Sep 30	Q2-FY20	Q2-FY19	Growth (y-o-y)	H1-FY20	H1-FY19	Growth (y-o-y)
Karnataka	911	880	3.4%	1,797	1,723	4.3%
Gujarat	773	653	18.4%	1,560	1,241	25.8%
Maharashtra	354	323	9.4%	686	590	16.3%
East India	202	159	26.8%	383	308	24.4%
Andhra Pradesh	195	176	11.1%	378	359	5.2%
Tamil Nadu	104	85	22.6%	192	160	20.1%
North India	58	18	232.7%	114	21	433.0%
	<b>2,597</b>	<b>2,294</b>	<b>13.2%</b>	<b>5,111</b>	<b>4,402</b>	<b>16.1%</b>

- Strong growth continues at several existing and new centers in Q2-FY20
  - Bhavnagar: +44.7% y-o-y
  - Borivali: +26.6% y-o-y
  - Suchirayu: +22.0% y-o-y
  - Chennai: +20.8% y-o-y
- New centers contributed Revenue of INR 373 Mn in Q2-FY20 vs 220 Mn in Q2-FY19
- Revenue from existing HCG centers grew 7% in Q2-FY20 on y-o-y basis



Financial Highlights



**Operating Highlights**



Key Financial  
Information



Project Updates

# HCG Centers: Q2-FY20 Operating Metrics

## No. of Centers

Q2-FY20:  
**24**

Q2-FY19:  
**24**

## Beds

Q2-FY20:  
**2,031**

Q2-FY19:  
**1,872**

## Avg. Occupancy Rate

Q2-FY20:  
**43.1%**

Q2-FY19:  
**45.3%**

↓ **217 bps**

## ALOS (Days)

Q2-FY20:  
**2.03**

Q2-FY19:  
**2.27**

↑ **24 bps**

## ARPOB (INR / Day)

Q2-FY20:  
**32,769**

Q2-FY19:  
**30,265**

↑ **8.3%**

## Revenue (INR mn)

Q2-FY20:  
**2,597**

Q2-FY19:  
**2,294**

↑ **13.2%**

## Operating EBITDA Margin

Q2-FY20:  
**15.3%**

Q2-FY19:  
**18.2%**

↓ **297 bps**


- ARPOB for existing centers at INR 33,536 against INR 30,306 in Q2-FY19
- Continuing reduction in ALOS to 2.03 on account of trend towards day care procedures and changing patient profile
- Operating EBITDA margins impacted with scale-up and losses of new centers
- Existing centers operating EBITDA margin declined by 176 bps to 20.6% in Q2-FY20 from 22.3% in Q2-FY19
- Existing centers operating EBITDA margin declined by 110 bps to 20.8% in H1-FY20 from 21.9% in H1-FY19

### Notes:

- (1) No. of Centers includes Cancer and Multispecialty hospitals operated under HCG brand and managed by HCG
- (2) Number of beds in operation as at the last day of the period
- (3) Occupied Bed Days calculated based on mid-day census
- (4) Average Occupancy Rate ("AOR") calculated as Occupied Bed Days divided by available bed days in the period
- (5) Average Revenue per Occupied Bed ("ARPOB") calculated as Revenue (gross for the hospital) divided by Occupied Bed Days
- (6) Average Length of Stay ("ALOS") calculated as Occupied Bed Days divided by number of admissions (including day care admissions)
- (7) Operating EBITDA margin before corporate expenses

Note: Effective 1 April 2019, the Company has adopted IND AS 116 'Leases' standards, applied to lease contracts existing on 1 April 2019. The effect of this adoption for the year ended 31 March 2019 have not been retrospectively adjusted. Unless specified, the EBITDA numbers exclude IND AS 116 adjustments.

# HCG Centers: Q2-FY20 Regional Highlights



Centers	Beds	AOR	ARPOB (INR/Day)	Revenue (INR MN)	Operating EBITDA %
<b>Karnataka</b>					
7	615	47.3%	35.6K	911	23.3%
		↓ -1.2%(1)	↑ +4.6%	↑ +3.4%	
<b>Gujarat</b>					
5	508	47.0%	35.2K	773	15.3%
		↑ +18.1%(1)	↑ +0.2%	↑ +18.4%	
<b>Maharashtra</b>					
3	336	40.8%	28.2K	354	NM
		↓ -1.4%(1)	↑ +11.3%	↑ +9.4%	
<b>Andhra Pradesh</b>					
3	177	31.8%	37.7K	195	21.3%
		↓ -17.9%(1)	↑ +35.4%	↑ +11.1%	
<b>East India</b>					
3	280	45.2 %	17.3K	202	16.0%
		↑ +19.9%(1)	↑ +5.8%	↑ +26.8%	

- COE ARPOB of INR 60.3k with 26.6% operating EBITDA margin
- H1-FY20 COE ROCE improved from 26.1% to **27.1%**
- Focus on margin and returns optimization across region

- Strong occupancy and revenue growth
- Bhavnagar oncology ramps-up with 45% revenue growth y-o-y
- EBITDA margin of existing cancer centers at **17%** for Q2-FY20

- Nashik center expansion driving enhancement of specialized service offerings in the region
- Borivali and Nagpur new centers ramping up with continued reduction in losses

- Center in Vizag continues to ramp up well
- Focus on improving revenue mix through reduction of scheme business



- Existing center EBITDA margin of 27.2%; improvement of 161 basis points
- Driven by improvements in patient and procedure mix
- Kolkata center operationalized

Note: Effective 1 April 2019, the Company has adopted IND AS 116 'Leases' standards, applied to lease contracts existing on 1 April 2019. The effect of this adoption for the year ended 31 March 2019 have not been retrospectively adjusted. Unless specified, the EBITDA numbers exclude IND AS 116 adjustments.

**Notes:**  
 (1) Increase / (Decrease) in Occupied Bed Days  
 (2) Growth numbers are year-on-year basis  
 (3) EBITDA before corporate expenses


● New centers  
 ● Existing centers

# Milann: Implementing Strategic Initiatives



	Q2-FY20	Q2-FY19	Growth
New Registrations	1,506	1,394	8.0%
IVF Cycles	579	510	13.5%
Revenue (INR Mn)	188	160	17.7%

- New Registrations growth at 8% y-o-y for Q2-FY20
- Whitefield continues to ramp-up well
- Leadership in attractive Bangalore market



(1) Centers in operation prior to April 1, 2016, i.e. Shivananda, JP Nagar and Indiranagar  
 (2) Mumbai Center exited in Q3-FY19



Financial Highlights



Operating Highlights



**Key Financial  
Information**

---



Project Updates

# Capital Expenditure and Net Debt

## Capital Expenditure

INR Million

	Q2-FY20	Q1-FY20
<b>HCG Centres</b>		
Existing Centres	65	44
Expansions	88	65
New Centres	285	240
	<b>438</b>	<b>349</b>
<b>Milann Centres</b>		
Existing Centres	0	5
New Centres	-	-
	<b>0</b>	<b>5</b>
<b>Total Capex</b>	<b>438</b>	<b>354</b>

1. Includes Security Deposit of INR 48 Mn in Q2-FY20.

## Net Debt

INR Million

	30-Sep-19	30-Jun-19
<b>Net Debt</b>		
Bank Debt <sup>(1)</sup>	5,151	4,626
Vendor Finance <sup>(2)</sup>	1,123	1,350
Capital Leases	563	563
Other Debt	7	18
Less: Cash and Equivalents <sup>(3)</sup>	(203)	(328)
Capital Leases - IND AS 116	5,567	5,748
<b>Net Debt post Ind AS adj.</b>	<b>12,207</b>	<b>11,977</b>
<b>Net Debt before Ind AS adj.</b>	<b>6,640</b>	<b>6,229</b>
<b>Debt in New Centres</b>		
Bank Debt	4,007	3,591
Vendor Finance	736	957
Other Debt	-	-
	<b>4,743</b>	<b>4,548</b>
<b>Net Debt (Excl. New Centres)</b>	<b>1,897</b>	<b>1,680</b>

1. Net of Bank balance held as margin money of INR 187 Mn and investment in fixed deposits of INR 43 Mn as at 30<sup>th</sup> Sep-19, margin money of INR 224 Mn and investment in fixed deposits of INR 39 Mn as at 30<sup>st</sup> Jun-19. The unamortised portion of processing fees amounting to INR 68 Mn as on 30<sup>th</sup> Sep-19 & INR 68 Mn as on 30<sup>th</sup> Jun-19 netted off against Bank Debt.
2. Includes Forex reinstatement of INR 25 Mn as at 30<sup>th</sup> Sep-19 and INR 0 Mn as at 30<sup>th</sup> Jun-19 on account of exchange rate fluctuation
3. Includes investment in mutual funds of INR 13 Mn as at 30<sup>th</sup> Sep-19 and INR 13 Mn as at 30<sup>th</sup> Jun-19.



Financial Highlights



Operating Highlights



Key Financial  
Information



**Project Updates**



## Additional 2 new HCG centers in FY2020

Location	Bed Capacity	Project Cost (INR mn)	Start Date
Jaipur, Rajasthan	50	410	Q2-FY19
Bhavnagar, Gujarat	NA	150	Q2-FY19
Nashik Phase II, Maharashtra	92	623	Q2-FY19
Rajkot, Gujarat	120	310	Q1-FY19
Kolkata, West Bengal	80	450	Q1-FY20
South Mumbai, Maharashtra	32	610	Q3-FY20

## 1 new Milann center launched in Q1 FY2019

Location	Start Date
Delhi	Q1-FY17
Chandigarh	Q3-FY17
Ahmedabad	Q4-FY18
Whitefield (Bangalore)	Q1-FY19

- **Existing centers** – HCG KR Road, HCG DR, HCG MSR, HCG Hubli, HCG Gulbarga, HCG MHIO Shimoga, HCC Ahmedabad, HMS Ahmedabad, HCG Bhavnagar, HCG Baroda, HCG Nashik, HCG Chennai, HCG Vijayawada, HCG Ongole, HCG Vizag, HCG Cuttack, HCG Ranchi
- **New centers** – HCG Suchirayu, HCG Rajkot, HCG Borivali, HCG Nagpur, HCG Jaipur, HCG Kolkata, HCG Africa

# THANK YOU



---

For updates and specific queries, please visit [www.hcgel.com](http://www.hcgel.com)  
or feel free to contact [investors@hcgoncology.com](mailto:investors@hcgoncology.com)

---

© 2019 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademark of HealthCare Global Enterprises Limited

In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.